MNKD · Investment summary · as of 3 August 2026
Priced close to what the business has demonstrated
Business type: Inflection · scaling but economically observable
The business does not meet the quality standard for its economic type.
At $3.80, MNKD requires a 7% five-year revenue growth rate to justify its enterprise value — less than the business already delivers, at 21%.
Estimates have moved fY2026E EPS 0.085 -> 0.1025 and FY2027E 0.1925 -> 0.2175 in the trailing 7 days (post-ReadyFlow approval). up into the print. House NTM ($428m) sits 14% below consensus NTM (~$499m); the divergence is ENTIRELY revenue (Furoscix ramp slope + Afrezza pediatric uptake), not multiple - at consensus revenue the same machinery gives $5.77. No aggregated Street price target wired for this name.
The strongest argument against this view: United Therapeutics displaces Tyvaso DPI with Tresmi - UT's own stated 'category killer', filing stated for 2026, launch the following year - and MannKind's 64%-of-revenue UT block (10% royalty = 36.3% of revenue at ~100% incremental margin; cost-plus manufacturing = 28.0%) stops growing and declines, against $325m of secured bullet debt (2030) carrying a first lien that includes the IP, ~$29.5m/yr cash interest vs $19.3m TTM operating cash flow, and negative book equity.
| Question | Evidence-based conclusion |
|---|---|
| What drives the business? | FY2023/FY2024/FY2025 operating income +$8.7m / +$72.6m / +$38.8m on revenue $199.0m / $285.5m / $349.0m; TTM to 31 March 2026 EBIT $14.8m on $360.8m. TTM operating cash flow $19.3m vs TTM net loss -$23.9m (accruals clean). |
| What do we forecast? | Revenue growth of 21% demonstrated; a terminal operating margin of 11%; an exit multiple of 4.2x. |
| What does Street forecast? | FY2026E EPS 0.085 -> 0.1025 and FY2027E 0.1925 -> 0.2175 in the trailing 7 days (post-ReadyFlow approval). up into the print. |
| Where do we differ? | House NTM ($428m) sits 14% below consensus NTM (~$499m); the divergence is ENTIRELY revenue (Furoscix ramp slope + Afrezza pediatric uptake), not multiple - at consensus revenue the same machinery gives $5.77. No aggregated Street price target wired for this name. On revenue growth, the difference between what the price requires and what the business has demonstrated is +0.8 percentage points. |
| What is it worth? | Twelve-month target $4.85, +28% from the struck price. Scenario-weighted expected return net of costs +8.6%. |
| Why now? | Date not announced — no dated event that would resolve the disagreement is on file |
| Date or window | Event | Thesis confirmed if | Thesis weakened or refuted if |
|---|---|---|---|
| each quarterly filing through Q2 2027 | United Therapeutics royalty revenue YoY growth <= 0% in two… | Neither leg of the condition opposite is met at this date | United Therapeutics royalty revenue YoY growth <= 0% in two consecutive quarters |
| Q3 2026, reported ~November 2026 | Furoscix + ReadyFlow net revenue below $20.0m in Q3 2026 | Furoscix + ReadyFlow net revenue at or above $20.0m in Q3 2026 | Furoscix + ReadyFlow net revenue below $20.0m in Q3 2026 |
| through mid-2027 | UT's Tresmi filing accepted with launch guided on or before 31… | Neither leg of the condition opposite is met at this date | UT's Tresmi filing accepted with launch guided on or before 31 December 2027 |
| Q4 2026, reported ~February 2027 | Afrezza gross revenue YoY < 0% in Q4 2026 despite the pediatric launch | Neither leg of the condition opposite is met at this date | Afrezza gross revenue YoY < 0% in Q4 2026 despite the pediatric launch |
United Therapeutics displaces Tyvaso DPI with Tresmi - UT's own stated 'category killer', filing stated for 2026, launch the following year - and MannKind's 64%-of-revenue UT block (10% royalty = 36.3% of revenue at ~100% incremental margin; cost-plus manufacturing = 28.0%) stops growing and declines, against $325m of secured bullet debt (2030) carrying a first lien that includes the IP, ~$29.5m/yr cash interest vs $19.3m TTM operating cash flow, and negative book equity. A 20% Tyvaso DPI decline removes ~$26m of royalty plus a similar order of manufacturing revenue - more than all of TTM EBIT ($14.8m). The royalty deceleration is already filed: +42.2% -> +25.2% -> +9.1%. GOING CONCERN, argued explicitly: not a 2026 event (2030 bullet; $40.0m minimum-liquidity covenant vs ~$136m pro-forma resources; management states 12+ months sufficiency).
Estimated probability 35%, against the 23% level at which the position would be resized. It sits above that level, so this case could not be carried at full size.
Falsifiable and fundamental — not one of them is a price condition.
On approach to the $4.85 target the case is reviewed rather than added to; a target reached is a reason to re-examine the position, not to hold it by default. The position is trimmed once forward expected return falls below 0% net of costs, because the capital has a better use elsewhere in the book.
| Criteria | Status | Investment meaning |
|---|---|---|
| Quality | Not met | Is the business worth owning under its declared economic type? |
| Valuation | Met | Is the operating path required by today's price achievable? |
| Liquidity | Met | Can the intended position be built and exited in the right vehicle? |
| Downside | Met | United Therapeutics displaces Tyvaso DPI with Tresmi - UT's own stated 'category killer', filing stated for 2026, launch the following year - and MannKind's 64%-of-revenue UT block (10% royalty = 36.3% of revenue at ~100% incremental margin; cost-plus manufacturing = 28.0%) stops growing and declines, against $325m of secured bullet debt (2030) carrying a first lien that includes the IP, ~$29.5m/yr cash interest vs $19.3m TTM operating cash flow, and negative book equity. |
| Momentum | Met | Does price action support or complicate entry timing? |
| Catalyst | Not determined | Is there a dated event that resolves the disagreement? Not established on the evidence on file. |
| Consensus | Not determined | Is the house-versus-Street disagreement identified and quantified? Not established on the evidence on file. |
Quality, valuation and liquidity can prevent a position on their own. The remaining four inform timing, sizing and monitoring, and never reject an investment by themselves.
The strongest case for mispricing is that the business already delivers +0.8 percentage points more growth than the price requires. The most important unresolved uncertainty is the permanent-loss mechanism: united Therapeutics displaces Tyvaso DPI with Tresmi - UT's own stated 'category killer', filing stated for 2026, launch the following year - and MannKind's 64%-of-revenue UT block (10% royalty = 36.3% of revenue at ~100% incremental margin; cost-plus manufacturing = 28.0%) stops growing and declines, against $325m of secured bullet debt (2030) carrying a first lien that includes the IP, ~$29.5m/yr cash interest vs $19.3m TTM operating cash flow, and negative book equity. The next evidence that should change the portfolio decision is the next scheduled results, or a daily close below $3.13, which forces an immediate review.